PRDM6 and medulloblastoma: As reported by others, utilising WGS might improve the identification of mutational signatures (e.g. deficiency of homologous recombination (HR)-mediated double strand break repair and sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors [36]), activated oncogenes through enhancer hijacking (e.g. Telomerase Reverse Transcriptase (TERT) in neuroblastoma [37] or growth factor independent 1 family protooncogenes GFI1 and GFI1B and PR domain-containing protein 6 (PRDM6) in medulloblastoma [38,39]), as well as microdeletions [17,40].